Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-4 of 4 for your search:
Drug:
yttrium Y 90 humanized epratuzumab
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Yttrium Y 90-Labeled Humanized Anti-CD22 Monoclonal Antibody LL2 in Patients with B-Cell Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CMMI-C-037A-97
, NCI-H99-0041, NCI-V99-1567, NCT00004084
2.
Phase I/II Study of Radioimmunotherapy with High Dose Yttrium Y 90 Humanized Anti-CD22 Monoclonal Antibody LL2 Followed By Autologous Peripheral Blood Stem Cell Rescue in Patients with B Cell Lymphomas or Waldenstrom's Macroglobulinemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 to 80
Sponsor:
NCI
Protocol IDs:
CMMI-C-037B-97
, UPCC-1499, NCI-H99-0040, NCT00004107
3.
Safety Study of NHL With 90Y-hLL2 IgG
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
IM-T-hLL2-06EU
, NCT00421395
4.
Phase I Study of Yttrium Y 90 Humanized Anti-CD22 LL2 in Combination With Salvage Chemotherapy and Autologous Peripheral Blood Stem Cell Rescue in Patients With Recurrent or Refractory B-Cell Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CMMI-C-037C-97
, NCI-V99-1569, NCT00004086
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute